Tobemstomig

{
  "id": "MLC-T-ONC-017218",
  "term": "Tobemstomig",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tobemstomig targets and binds to both PD-1 and LAG-3 expressed on T cells and inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation. This may lead to cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation.",
  "synonyms": [
    "anti-PD1/anti-LAG3 bispecific antibody RO7247669",
    "anti-PD-1/Anti-LAG-3 bispecific antibody RO7247669"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tobemstomig/"
}